An article previewing new subgroup, imaging and biomarker analyses that reframe an oral Alzheimer’s therapy’s clinical story and future directions.
Key Takeaways
- By the traditional standards of drug development, that could have been the end of the story
- Company is returning to this year’s Alzheimer’s Association International Conference (AAIC)
- Company is also reporting encouraging changes in biological markers linked to disease progression